Transcode Therapeutics (RNAZ) Total Current Liabilities (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Total Current Liabilities came in at $5.4 million in Q1 2026, up 114.31% YoY from $2.5 million in Q1 2025, and up 53.93% on a QoQ basis from $3.5 million in Q4 2025.
Transcode Therapeutics (RNAZ) Total Current Liabilities (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Total Current Liabilities data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Total Current Liabilities rose 114.31% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 114.31% YoY) and the FY2025 annual result came in at $3.5 million, up 26.06% from the prior year.
- Total Current Liabilities climbed to $5.4 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $5.6 million in Q3 2023 to a low of $1.6 million in Q2 2025.
- A 5-year average of $3.3 million and a median of $3.5 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 194.7% — and 2024, when it tumbled 59.2%.
- Tracing RNAZ's Total Current Liabilities over 5 years: stood at $4.3 million in 2022, then dropped by 19.71% to $3.5 million in 2023, then retreated by 20.59% to $2.8 million in 2024, then gained by 26.06% to $3.5 million in 2025, then jumped by 53.93% to $5.4 million in 2026.
- The last three Total Current Liabilities figures came in at $5.4 million (Q1 2026), $3.5 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Transcode Therapeutics | 2.81 Mn | 2.81 Mn | - | 5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.38 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Sep 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Sep 30, 2023 | 5.60 Mn |
| Jun 30, 2023 | 3.52 Mn |
| Mar 31, 2023 | 5.45 Mn |
| Dec 31, 2022 | 4.35 Mn |
| Sep 30, 2022 | 3.77 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | 1.85 Mn |
| Dec 31, 2021 | 2.53 Mn |
| Sep 30, 2021 | 2.20 Mn |
| Jun 30, 2021 | 1.53 Mn |